Nevertheless, the seclusion of the peritoneal cavity as a self-contained therapeutic space may allow such therapeutic concepts.2 In the past, intraperitoneal antibody therapies have been already proven practicable in advanced ovarian cancer.50 As most EOC patients are diagnosed with metastatic disease, a CXCR3-directed therapy to prevent metastatic spread is only conceivable as part of an adjuvant therapy after primary debulking surgery. This evidence concerns the gene CXCR3 and ovarian carcinoma.